Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Daiichi Sankyo Co Stock News

DSNKYOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$22.60

At close: Apr 15 EDT

$22.20

-0.40-1.77%

Pre-Market: Apr 14, 9:29 AM EDT

Daiichi Sankyo Co (DSNKY) Forecast

News

Earnings Daiichi Sankyo Co (DSNKY) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest Daiichi Sankyo Co Stock News | OTC:DSNKY | Benzinga

Get the latest news on Daiichi Sankyo Co stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Daiichi Sankyo Co performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, March 21, 2025

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
Vandana Singh - Mar 21, 2025, 12:31PM

Friday, January 31, 2025

CORRECTION: Daiichi Sankyo Co Q3 EPS $0.22 Up...
Benzinga Newsdesk - Jan 31, 2025, 9:04AM
Reported Earlier, Daiichi Sankyo And AstraZen...
Benzinga Newsdesk - Jan 31, 2025, 1:45AM
Reported Earlier, Daiichi Sankyo Appoints Hir...
Benzinga Newsdesk - Jan 31, 2025, 1:41AM

Tuesday, January 28, 2025

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
Vandana Singh - Jan 28, 2025, 10:29AM

Tuesday, January 21, 2025

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
Vandana Singh - Jan 21, 2025, 12:54PM
Reported Friday, FDA Approves Daiichi Sankyo ...
Benzinga Newsdesk - Jan 21, 2025, 1:41AM

Monday, January 13, 2025

FDA Grants Priority Review to Daiichi Sankyo ...
Benzinga Newsdesk - Jan 13, 2025, 2:14AM

Friday, December 06, 2024

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
Vandana Singh - Dec 6, 2024, 9:03AM
Reported Earlier, Daiichi Sankyo And AstraZen...
Benzinga Newsdesk - Dec 6, 2024, 2:29AM

Tuesday, November 12, 2024

Daiichi Sankyo And AstraZeneca Submit New BLA...
Benzinga Newsdesk - Nov 12, 2024, 2:12AM

Monday, November 11, 2024

Reported Sunday, Alteogen Secures Exclusive L...
Benzinga Newsdesk - Nov 11, 2024, 3:15AM

Thursday, October 31, 2024

Daiichi Sankyo Co expects FY2024 GAAP EPS Gui...
Benzinga Newsdesk - Oct 31, 2024, 6:16AM
Daiichi Sankyo Co Q2 EPS $0.22 Up From $0.14 ...
Benzinga Newsdesk - Oct 31, 2024, 5:52AM

Monday, September 23, 2024

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
Vandana Singh - Sep 23, 2024, 7:44AM

Tuesday, September 17, 2024

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Vandana Singh - Sep 17, 2024, 7:58AM

Tuesday, September 10, 2024

AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
Vandana Singh - Sep 10, 2024, 8:16AM

Monday, September 09, 2024

Reported Saturday, Daiichi Sankyo And Merck's...
Benzinga Newsdesk - Sep 9, 2024, 4:13AM

Monday, August 19, 2024

Daiichi Sankyo And AstraZeneca's ENHERTU Rece...
Benzinga Newsdesk - Aug 19, 2024, 2:29AM

Wednesday, August 07, 2024

Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
Surbhi Jain - Aug 7, 2024, 9:16AM

Tuesday, August 06, 2024

Daiichi Sankyo, Merck Expand Partnership To C...
Benzinga Newsdesk - Aug 6, 2024, 6:50AM

Tuesday, July 30, 2024

Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
Vandana Singh - Jul 30, 2024, 8:45AM

Thursday, June 27, 2024

FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
Vandana Singh - Jun 27, 2024, 10:13AM

Monday, June 03, 2024

Reported Earlier, Daiichi Sankyo And AstraZen...
Benzinga Newsdesk - Jun 3, 2024, 2:49AM

Tuesday, May 28, 2024

Why Is AstraZeneca Stock Trading Lower On Tuesday?
Vandana Singh - May 28, 2024, 2:32PM

Monday, April 29, 2024

Double Good News For AstraZeneca's Breast Cancer Drugs
Vandana Singh - Apr 29, 2024, 9:25AM

Monday, April 08, 2024

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
Vandana Singh - Apr 8, 2024, 10:34AM

Tuesday, April 02, 2024

Daiichi Sankyo And AstraZeneca's Datopotamab ...
Benzinga Newsdesk - Apr 2, 2024, 2:18AM

Monday, February 19, 2024

Daiichi Sankyo And AstraZeneca Announced Earlier, BLA For Datopotamab Deruxtecan Accepted By FDA, Potential First TROP2 Directed ADC For Non-Squamous NSCLC After Prior Therapy
Charles Gross - Feb 19, 2024, 10:56AM

Monday, January 29, 2024

Daiichi Sankyo And AstraZeneca's Supplemental...
Benzinga Newsdesk - Jan 29, 2024, 2:19AM

Thursday, January 25, 2024

What's Going On With Pfizer Stock Today?
Vandana Singh - Jan 25, 2024, 9:26AM

Wednesday, January 03, 2024

Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
Nabaparna Bhattacharya - Jan 3, 2024, 9:47AM

Friday, December 22, 2023

The FDA Has Accepted And Granted Priority Rev...
Benzinga Newsdesk - Dec 22, 2023, 8:04AM

Wednesday, December 20, 2023

Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
Surbhi Jain - Dec 20, 2023, 8:38AM

Friday, October 20, 2023

Daiichi Sankyo And Merck Announce Collaborati...
Benzinga Newsdesk - Oct 20, 2023, 3:15AM

Friday, September 22, 2023

Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
Vandana Singh - Sep 22, 2023, 7:46AM
AstraZeneca- Daiichi Sankyo's Datopotamab Der...
Benzinga Newsdesk - Sep 22, 2023, 2:54AM

Monday, September 11, 2023

AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
Vandana Singh - Sep 11, 2023, 9:59AM
AstraZeneca, Daiichi Sankyo's Datopotamab Der...
Benzinga Newsdesk - Sep 11, 2023, 4:29AM

Friday, July 21, 2023

FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
Vandana Singh - Jul 21, 2023, 9:44AM

Tuesday, July 04, 2023

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
Lara Goldstein - Jul 4, 2023, 10:21AM

Monday, July 03, 2023

AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
Vandana Singh - Jul 3, 2023, 5:50AM
Datopotamab Deruxtecan Jointly Developed By D...
Benzinga Newsdesk - Jul 3, 2023, 2:11AM

Tuesday, June 27, 2023

Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
Lara Goldstein - Jun 27, 2023, 5:00PM

Monday, March 20, 2023

Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
Vandana Singh - Mar 20, 2023, 10:27AM

Monday, March 06, 2023

AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
Vandana Singh - Mar 6, 2023, 10:03AM

Friday, January 13, 2023

Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
Vandana Singh - Jan 13, 2023, 11:16AM

Monday, December 19, 2022

AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
Vandana Singh - Dec 19, 2022, 8:27AM

Friday, December 09, 2022

AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
Vandana Singh - Dec 9, 2022, 6:14AM

Wednesday, December 07, 2022

AstraZeneca-Daiichi Sankyo's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
Vandana Singh - Dec 7, 2022, 12:01PM

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved